We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Karyopharm Therapeutics Inc. (KPTI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.3400 |
| Open | 1.3400 |
| Bid | 1.2000 x 300 |
| Ask | 1.2300 x 300 |
| Day's Range | 1.1800 - 1.3450 |
| 52 Week Range | 0.6170 - 4.8700 |
| Volume | |
| Avg. Volume | 1,742,938 |
| Market Cap | 140.382M |
| Beta (5Y Monthly) | 0.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2500 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.57 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for KPTI
Related Research
- Karyopharm Therapeutics Inc.Daily – Vickers Top Buyers & Sellers for 10/06/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 years agoArgus Research
PR NewswireKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 79,800 restricted stock units (RSUs) to five newly-hired employees. These RSU awards were granted as of March 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Na
- PR Newswire
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and present at the Barclays 26th Annual Global Healthcare Conference in a fireside chat on Wednesday, March 13, 2024 at 9:00 a.m. ET in Miami Beach, FL.
GuruFocus.comInsider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...
President and CEO Richard Paulson executed a sale of 99,844 shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) on March 1, 2024, according to a recent SEC Filing.
Insider MonkeyKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript February 29, 2024 Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS is $-0.36 EPS, expectations were $-0.29. FDS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name […]
- Thomson Reuters StreetEvents
Q4 2023 Karyopharm Therapeutics Inc Earnings Call
Q4 2023 Karyopharm Therapeutics Inc Earnings Call
Motley FoolKaryopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
KPTI earnings call for the period ending December 31, 2023.
ZacksKaryopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -24.14% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023. In addition, Karyopharm highlighted select corporate milestones and provided an overview of its key clinical development programs.
InvestorPlace7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum. This is a good time to remind you of all the reasons you shouldn’t buy biotech penny stocks. The first reason centers on the last two words. While many of these companies may claim advanced clinical data and whatnot, the reality is that many if not most players in this field wil
- PR Newswire
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 29, 2024. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, February 29, 2024, to discuss the financial results and other company updates.
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| MGNX MacroGenics, Inc. | |||
| HRTX Heron Therapeutics, Inc. | |||
| TGTX TG Therapeutics, Inc. | |||
| FGEN FibroGen, Inc. | |||
| ATRA Atara Biotherapeutics, Inc. |
Similar to KPTI
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| FGEN FibroGen, Inc. | |||
| MGNX MacroGenics, Inc. | |||
| ATRA Atara Biotherapeutics, Inc. | |||
| ADCT ADC Therapeutics SA | |||
| EIGR Eiger BioPharmaceuticals, Inc. |
Analyst Price Targets (7)
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/1/2024 | |
| Maintains | Piper Sandler: Overweight to Overweight | 11/3/2023 | |
| Maintains | RBC Capital: Outperform to Outperform | 11/3/2023 | |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 8/7/2023 | |
| Maintains | Piper Sandler: Overweight to Overweight | 8/3/2023 | |
| Maintains | RBC Capital: Outperform to Outperform | 8/3/2023 |
Company Profile
85 Wells Avenue
Suite 210
Newton, MA 02459-3298
United States
617 658 0600
https://www.karyopharm.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 325
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
